TABLE 6.

Genetic linkage of grlA and grlB mutations and resistance by transformation: incross of grlBA⁺

Donor characteristics		Recipient characteristics		MIC (μg/ml) for recipient		MIC (μg/ml) for susceptible transformants		% Susceptible transformants (no. of susceptible transformants/no. of total transformants)
Strain	Genotype	Strain	Genotype	GAT	CIP	GAT	CIP
ISP2133	trp-489 Ω(chr::Tn917lac)2	G1	grlA (Lys23Asn)	0.25–0.5	0.5–1.0	0.125	0.25	21 (15/70)
		G4	grlA (Ala176Gly)	0.5–1.0	2.0	0.25	0.5	20 (21/107)
		GB	grlB (Pro25His)	0.5–1.0	1.0–2.0	0.125	0.25	30 (31/104)
		MT5224c4	grlA (Ser80Phe)	0.032	1.0	0.008	0.25	21 (8/38)
ISP2134	thrB494 Ω(chr::Tn917lac)1	G1	grlA (Lys23Asn)	0.25–0.5	0.5–1.0	0.125	0.25	15 (8/52)
		G4	grlA (Ala176Gly)	0.5–1.0	2.0	0.25	0.5	11 (12/113)
		GB	grlB (Pro25His)	0.5–1.0	1.0–2.0	0.125	0.25	11 (12/108)
		MT5224c4	grlA (Ser80Phe)	0.032	1.0	0.008	0.25	5 (8/171)

^aGAT, gatifloxacin; CIP, ciprofloxacin.